[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369681-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369681-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","implementation-and-outcome-of-personalized-treatment-strategies-in-advanced-genitourinary-cancers-original-article","Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers - Original article","","Outcome is dismal in patients with advanced genitourinary (GU) cancers refractory to standard treatments. To address limited evidence for molecular tumor board–guided personalization, a retrospective cohort of GU cancer patients discussed at Charité from 2016 to 2023 was analyzed. Clinical benefit required complete/partial response, stable disease beyond 6 months, or a progression-free survival ratio between molecularly matched therapy and prior non-matched therapy exceeding 1.3. Molecularly matched therapy options were identified for most patients and responses occurred in heavily pretreated cases.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/implementation-and-outcome-of-personalized-treatment-strategies-in-advanced-genitourinary-cancers-original-article/369681/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/implementation-and-outcome-of-personalized-treatment-strategies-in-advanced-genitourinary-cancers-original-article/369681.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was molecular tumor board (MTB)–guided personalized treatment investigated in advanced GU cancers?","Question",{"text":63,"@type":64},"Outcome is poor for advanced GU cancers that are refractory to standard treatments, and molecular analyses with MTB case discussions are increasingly used to support personalized management. However, data for this approach in GU malignancies were lacking.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study define clinical benefit?",{"text":68,"@type":64},"Clinical benefit included complete response, partial response, or stable disease lasting more than 6 months, or a progression-free survival ratio greater than 1.3 comparing molecularly matched therapy to previous non-molecularly matched therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were reported after molecularly matched therapy was identified and applied?",{"text":72,"@type":64},"At least one molecularly matched therapy option was identified for 78/115 patients, and 25 patients received molecularly matched therapy. Clinical benefit was observed in 8/28 applied molecularly matched therapies, and a progression-free survival ratio above 1.3 was achieved in eight patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369681,1791531214,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","ORIGINAL ARTICLE  \nImplementation and outcome of personalized treatment strategies in advanced genitourinary cancers  \nA. Klostermann1∗†, T. Debertshäuser1 , 2†, M. Benary1 , 2†, N. Biernath3†, B. Erber3†, R. Tahbaz3†, M. Möbs4†, M. Joosten4†,  \nW. D. Schmitt4†, T. Kim5†, I. Jelas1 , 6†, L. Chai6†, Y. Jegodka1†, U. Keller5 , 7†, D. Beule2, S. Ochsenreither1 , 5 , 7†,  \nM. De Santis3 , 8†, T. Schlomm3†, U. Keilholz1 , 7†, M. Knödler1†‡ & D. T. Rieke1 , 5 , 7∗†‡  \n1Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Berlin; 2Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin; 3Department of Urology, Charité -Universitätsmedizin Berlin, Berlin; 4Institute of Pathology, Charité -Universitätsmedizin Berlin, Berlin; 5Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin; 6Department of Hematology, Oncology and Cancer Immunology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin; 7German Cancer Consortium (DKTK) and German Cancer Research Center, Partner Site Berlin, Berlin, Germany; 8Department of Urology, Medical University of Vienna, Vienna, Austria  \nAvailable online xxx  \nBackground: Outcome is dismal in patients with advanced genitourinary (GU) cancers refractory to standard treatments. Molecular analyses and subsequent discussion of cases in specialized molecular tumor boards (MTBs) are increasingly incorporated into clinical management to facilitate personalized treatment. Data on this approach are lacking for GU malignancies.  \nMethods: We conducted a retrospective analysis of patients with GU cancers discussed in the MTB at the Charité between 2016 and 2023. Ethics approval was obtained for prospective follow-up of patients after written informed consent and for retrospective data analysis. Clinical benefit was defined as complete response (CR), partial response (PR) or stable disease (SD) >6 months or a progression-free survival (PFS) ratio between molecularly matched therapy (MMT) and previous non-MMT > 1.3. Outcome was assessed by the investigators.  \nResults: Among 126 identified MTB patients, most patients had a rare tumor type (n = 59), followed by adenocarcinoma of the prostate (n = 45), urothelial carcinoma (n = 17) and clear-cell renal carcinoma (n = 5) . Molecular profiling included immunohistochemistry (n = 80), panel sequencing (n = 110) and/or whole-exome/-transcriptome sequencing (n = 21) . Eleven patients died before the final MTB discussion. At least one treatment option for MMT was identified for 78/115 patients (68%) . Twenty-five patients were treated with an MMT (22%), three of whom subsequently received a second MMT. Eighteen MMTs were given in an off-label setting and two within clinical trials. A clinical benefit was observed in 8/  \n28 (28 .6%) applied MMTs. A PFS-ratio > 1.3 was achieved in eight patients. Among patients with rare entities discussed (n = 54), 42 patients had at least one MMT option (78%), with 19 patients receiving at least one MMT (35%) . Conclusion: For a majority of GU cancer patients an MMT was identified and responses were seen in heavily pretreated patients. Additional controlled trials and integration of comprehensive molecular analyses and subsequent personalized therapy should be considered for patients with GU cancers, especially those with rare histologies.  \nKey words: molecular tumor board, targeted therapy, precision oncology, genitourinary cancer, real-world data  \nBACKGROUND/INTRODUCTION  \nThe identification of molecular alterations in cancers and subsequent targeted treatment is expected to improve outcome for a subset of patients. This concept of  \n*Correspondence to: Drs Anna Klostermann, D.T. Rieke, Charité Comprehensive Cancer Center, Charitéplatz 1, 10117 Berlin, Germany  \nE-mails: [annasoraya.klostermann@alumni.charite.de](annasoraya.klostermann@alumni.charite.de) (A. Klostermann) or [damian.rieke@charite.de](damian.rie","cbCaieTVZUR8pggz","https://ap.wps.com/l/cbCaieTVZUR8pggz","pdf",833024,"English","# Background/Introduction\n# Methods\n# Results\n# Conclusion\n# Molecularly matched treatment in GU malignancies\n# Comprehensive molecular analyses in GU malignancies","[{\"question\":\"Why was molecular tumor board (MTB)–guided personalized treatment investigated in advanced GU cancers?\",\"answer\":\"Outcome is poor for advanced GU cancers that are refractory to standard treatments, and molecular analyses with MTB case discussions are increasingly used to support personalized management. However, data for this approach in GU malignancies were lacking.\"},{\"question\":\"How did the study define clinical benefit?\",\"answer\":\"Clinical benefit included complete response, partial response, or stable disease lasting more than 6 months, or a progression-free survival ratio greater than 1.3 comparing molecularly matched therapy to previous non-molecularly matched therapy.\"},{\"question\":\"What outcomes were reported after molecularly matched therapy was identified and applied?\",\"answer\":\"At least one molecularly matched therapy option was identified for 78/115 patients, and 25 patients received molecularly matched therapy. Clinical benefit was observed in 8/28 applied molecularly matched therapies, and a progression-free survival ratio above 1.3 was achieved in eight patients.\"}]","Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers - Original article | PDF",1790184090,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb1eb7e5e951d36fca1b143ddf17a1ec.webp",983,1269,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25faf5fde7ef2c8c267d0ef9d7ee337d.webp",982,1268,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45eb0f6ab2cd7cf4d65f20ef5c2eb9e2.webp",981,1266,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61bb9a59ac87444179b45b0a0678547e.webp",980,1265]